Milestones

2013
Path Therapeutics incorporated
2014
$3M Brain Canada Grant awarded to develop MitoREAD
2015
Platform patent filed for MitoREAD
2017
Grants awarded from Dravet Canada and Hotchkiss Brain Institute to pursue drug discovery
2018
First publication of MitoREAD as a drug screening platform in the journal Brain (Impact Factor > 14)
2018
US$300K pre-seed investment received from AJ Therapeutics to further validate novel druggable targets identified by MitoREAD
2020
US$2M seed funding received from Viva BioInnovator to launch drug discovery programs against novel druggable targets
2020
Methods patent filed for PDE4 in epilepsy
2021
Presentation of MitoREAD at Sweet Pharma Day (Montreal, QC)
2024
Relaunched as Stream Neurosciences to advance drug discovery in epilepsy and cognition
2024
Poster presented at AES 2024 summarizing preclinical efficacy of PDE4B allosteric inhibition on seizure activity and cognition